Patent intelligence · CA
CA 2506727
TRAITEMENT DE LA MALADIE DE HUNTINGTON AU MOYEN D'ACIDE EICOSAPENTAENOIQUE
TRAITEMENT DE LA MALADIE DE HUNTINGTON AU MOYEN D'ACIDE EICOSAPENTAENOIQUE
Patent details — CA 2506727
- Jurisdiction
- CA
- Status
- expired
- Grant date
- Jun 17, 2004
- Expiration
- Jun 12, 2024
- Applicant
- AMARIN NEUROSCIENCE LTD [GB]
- CPC classes
- A61K 31/ 00 A I, A61K 31/ 20 A I, A61K/3100, A61K/3120
Quick answer
CA 2506727 (TRAITEMENT DE LA MALADIE DE HUNTINGTON AU MOYEN D'ACIDE EICOSAPENTAENOIQUE) is held by AMARIN NEUROSCIENCE LTD [GB]. Status: expired. Granted Jun 17, 2004. Expires Jun 12, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AMARIN NEUROSCIENCE LTD [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 00 A I, A61K 31/ 20 A I, A61K/3100, A61K/3120, A61K31/00, A61P 25/ 28 A I
Frequently asked questions
What is US patent 2506727?
CA 2506727 (TRAITEMENT DE LA MALADIE DE HUNTINGTON AU MOYEN D'ACIDE EICOSAPENTAENOIQUE) is held by AMARIN NEUROSCIENCE LTD [GB]. Status: expired. Granted Jun 17, 2004. Expires Jun 12, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2506727?
AMARIN NEUROSCIENCE LTD [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews.
When does CA 2506727 expire?
Our index shows an expiration date of Jun 12, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.